Table 5.

Survival outcomes in selected adjuvant studies of resected pancreatic cancer

Study	Regimen	Sample size	Positive margins (%)	Nodal involvement (%)	Local recurrence (%)*	RFS (mo)	Median (mo)
GITSG, 1985	5-FU+XRT → 5-FU	21	0	28	33	11	20
EORTC, 1999	5-FU+XRT	104	19	47	36	17.4†	17.1
ESPAC-1, 2001	5-FU+XRT → 5-FU + LV	75	-	-	-	-	19.9
CONKO-001, 2007	Gem	179	19	71	34	13.4‡	22.1‡
ROTG 97-04, 2008	Gem; 5-FU/XRT → gem	221	35	68	23	-	20.6
ESPAC-3, 2010	Gem	537	35	73	-	14.3	23.6
Bao et al, 2011 (9)	Erlotinib+FDR gem	25	0	64	59	14§	~24§, ‖
This study	Erlotinib+capecitabine+IMRT → erlotinib+gem	48	17	85	27	15.6	24.4

Abbreviations 5-FU = 5-fluorouracil; CONKO = Charité Onkologie; ESPAC = European Study Group for Pancreatic Cancer; EORTC = European Organization for Research and Treatment of Cancer; FDR = fixed dose rate; Gem = gemcitabine; GITSG = Gastro-Intestinal Study Group; IMRT = intensity modulated radiation therapy; LV = leukovorin; RFS = recurrence-free survival; ROTG = Radiation Therapy Oncology Group; XRT = radiation therapy. Unless otherwise indicated, event times for RFS and median survival were measured from the date of surgical resection.

^*Including synchronous local and distant recurrences.

^†Including periampullary cancer.

^‡Event time from randomization.

^§Event time from the start of adjuvant therapy.

^‖Median survival was not reached in this study, but the 2-year overall survival was 53%, suggesting a median survival of approximately 24 months